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ABSTRACT 
 Lysyl oxidase (LOX) and the four lysyl oxidase like proteins, LOXL, LOXL2, 
LOXL3 and LOXL4, are copper-containing amine oxidases constitute a heterogeneous 
family of enzymes that oxidize primary amine substrates to reactive aldehydes, catalyzing 
the cross-linking of extracellular matrix (ECM) proteins. LOXL2 induces epithelial-to-
mesenchymal transition (EMT), which is associated with hypoxia, enhanced invasion, 
cancer metastasis and poorer cancer prognosis. Furthermore, upregulation of LOXL2 
mRNA and/ or protein levels has been detected in undifferentiated breast, colon, 
esophagus and larynx carcinomas. The aim here is to create and optimize a method to 
produce large yields of enzymatically active recombinant LOXL2 protein from 
mammalian cells. Two viral transductions systems were used to transfect CHO-K1 cells 
to overexpress LOXL2 protein. Comparing lentivirus transduction with adenovirus 
transduction, it was found that adenovirus transduction expressed 2.18 fold the amount of 
enzymatically active LOXL2 compared to lentivirus transduction (P<0.05). The average 
LOXL2 yield of lentivirus and adenovirus transduction systems as calculated by BCA 
assay was 184.5 µg and 403 µg, respectively. The average specific LOXL2 enzymatic 
		 vi 
activity were calculated using an Amplex red assay and found to be 0.443 and 0.444 
nmol/µg of LOXL2 in 30 minutes in lentivirus and adenovirus methods, respectively, 
with no statistically significant difference (P>0.05). Expression and purification of 
LOXL2 were confirmed by SDS-PAGE and Western blot. Optimizing this method to 
purify large yields of LOXL2 is a practical aid in revealing the exact structure and 
function of the LOX family of proteins.  
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Introduction and Literature Review: 
Collagen and elastin: 
 Collagen is the main protein that is responsible for the structural integrity of the 
connective tissue of vertebrates and other multicellular organisms. In various tissue types, 
collagen fibrils provide specific characteristics in terms of resistance and tensile strength. 
Depending on the architectural arrangement and diameter of these collagen fibrils and 
suprafibrils, tissues like bone, cartilage, tendons and skin differ in their structural 
characteristics. There are more than 20 types of collagen in the body but the most 
abundant types are type I, II and III. Type I collagen consists of three amino acid chains 
in the three dimensional shape of the triple helix which consists of 2 identical (α1) chains 
and 1 slightly different (α2) chain. Each chain sequence is arranged in glycine-proline-X 
which X is any other amino acid other than glycine and proline. This gly-pro-X sequence 
is considered the most common motif in building of this polypeptide chain (Hulmes, D et 
al. 2002). 
 Collagen biosynthesis is a very meticulous process. All fibrillar collagens are 
synthesized and secreted into the extracellular matrix in the form of soluble precursors, 
procollagens (Hulmes, D et al. 2002). In this process, the polypeptides are released into 
the rough endoplasmic reticulum (RER). Hydroxylation of proline and lysine residues 
occurs in each polypeptide by prolyl hydroxylase and lysyl hydroxylase respectively, and 
glycosylation occurs by the addition of either glucose or galactose to the hydroxylated 
lysine residues. After the glycosylation step, disulfide bonds form in inter and intra-chain 
areas providing structural stability of each chain and causing the triple-helix three-
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dimensional shape to form. In the Golgi apparatus, the final post-translation modification 
that occurs before the secretion of the procollagen into the extracellular space is the 
addition of oligosaccharides to certain asparagine residues in the C-terminal propeptide. 
Extracellularly, pro-collagen C and N-proteinases remove their respective terminals on 
procollagen resulting in the maturation of collagen which is arranged into fibrils and 
subsequent cross-linking occurs to form the final architecture of extracellular matrix 
(ECM) with the help of lysyl oxidase (Hulmes, D et al. 2002). 
 
 Elastin is the major component of elastic fibers that is found in the extracellular 
matrix of tissues like lungs, large blood vessels and other elastic tissues. It provides these 
tissues with the elasticity and resilience required for their function in the body. Their 
ability to elastically stretch and recoil repetitively and reversibly without damaging these 
tissues is related to the rubber-like properties of elastin. The other major component of 
elastic fibers is the fibrillar component known as microfibrils which serve as a scaffold 
that facilitates the alignment and cross-linking of elastin molecules. This cross-linking is 
catalyzed by one or more members of lysyl oxidase (LOX) family (Mecham 2007). 
Elastin, like collagen, is very rich glycine and proline. Approximately 75% of the entire 
amino acid sequence of elastin is made up of just four hydrophobic amino acids: glycine, 
valine, alanine and proline residues representing over 30% of the sequence. However, 
they differ in some of their post-translation modifications. Elastin residues are not 
glycosylated. Furthermore, very few proline residues are hydroxylated in elastin unlike 
collagen that contains a high amount of hydroxyproline and hydroxylysine molecules 
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(Muiznieks, L et al. 2010). Tropoelastin is the precursor of mature elastin. It is subjected 
to minor post-translational modifications before its release extracellularly. Once 
tropoelastins are secreted extracellularly they become covalently cross-linked by lysyl 
oxidase (Alberts, B et al. 2002). 
 
 
Lysyl Oxidase family of proteins: 
 Lysyl oxidase (LOX) is a copper-dependant amine oxidase that is required for the 
covalent cross-linking of collagen and elastin fibrils in the extracellular matrix of the 
connective tissue. By oxidizing lysine residues and producing a reactive aldehyde group, 
lysyl oxidase initiates covalent crosslinkages between these protein fibrils (Kagan 2003). 
Lysyl oxidase family consists of LOX and other 4 paralogues: LOX-like 1-4 that share a 
highly conserved C-terminal structure that is responsible for the enzymatic activity of the 
LOX family. This C-terminal structure consists of different domains with specific 
function: copper-binding domain, putative metal-binding domains, a cytokine receptor-
like domain and tyrosine and lysine residues of lysyl-tyrosylquinone cofactor. Together, 
the copper-binding motif and lysyl-tyrosylquinone (LTQ) cofactors are determinants of 
the enzymatic activity of  this family of proteins (Csiszar, K. 2001). In contrast, the N-
terminal of LOX family members differs in structure which may indicate a different but 
related individual function such as cell growth control, tumor suppression, and 
chemotaxis (J Molnar 2003). The N-terminal region of LOXL 2, 3 and 4 contain 4 
scavenger receptors cysteine-rich (SRCR) which are not present in LOX and LOXL1. 
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These SRCR domains are found in cell membrane-associated proteins that function in 
cell adhesion (Lucero, HA et al. 2006). 
 
 LOX oxidizes lysine residues present in collagen and elastin fibrils to alpha-
aminoadipic-delta-semialdehyde. This permits the covalent cross-linking between these 
fibrils to form by spontaneous condensation of these aldehydes with neighboring 
aldehyde and other amino acid groups. This, in turn, stabilizes and provides collagen and 
elastin with their specific mechanical properties in the ECM of different connective 
tissues (Kagan 1997). Therefore, any change in LOX regulation can result in ECM 
abnormalities. In animal studies conducted about osteolathyrism, an abnormality 
characterized by decreased cross-linking of collagen and elastin, LOX was inhibited by 
either nutritional copper-deficiency or diet supplementation of β-aminopropionitrile 
(BAPN), which is a potent inhibitor of LOX (Dawson, DA et al. 2002). The 
dysregulation either by up-regulation or down-regulation of LOX can be responsible for 
the onset and progression of multiple pathologies affecting the connective tissue, such as 
fibrotic processes, tumor progression, metastasis, and neurodegenerative and 
cardiovascular diseases. Inhibitors of the LOX enzyme may be useful in preventing 
tumor progression and metastasis as well as treating other fibrotic diseases that involve 
the remodeling of the extracellular matrix (Rodriguez, C. et al 2008).  
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Importance of LOXL2 in Cancer, Metastasis, and ECM: 
 Recent studies have shown that LOX is involved with stabilization of the ECM as 
well as influencing cell proliferation (Saad et al. 2010, Baker et al. 2011). Furthermore, a 
deficiency of the LOX gene resulted in decreased osteoblastic differentiation providing 
the evidence of LOX role in bone formation (Pischon N et al. 2009). In spite of these 
roles, studies have shown that LOX and LOXL2 promote tumor cell invasion and 
metastasis (Nishioka, T et al. 2012).  
 
 LOX has an important central role in the morphogenesis and repair of connective 
tissues of the cardiovascular, respiratory, skeletal, and other systems of the body (Kagan, 
H et al. 2003). Therefore, the important role of the LOX family in stabilization and 
maintenance of ECM implies its involvement in pathological conditions affecting 
connective tissues such as fibrotic processes, neurodegenerative and cardiovascular 
disease, and tumor progression and metastasis. Studies have shown that LOX is an agent 
of various fibrotic conditions. Despite the early evidence proposing LOX as a tumor 
suppressor, LOX and LOXL2 induce epithelial-to-mesenchymal transition (EMT), which 
is associated with hypoxia, and enhanced invasion (Erler et al. 2013). Hypoxia is a 
common feature of many malignancies. Cancer cells’ adaptive ability to survive in low 
oxygen levels are better than normal cells (Nishioka, T et al. 2012). Hypoxia induces 
tumor expression of LOX through hypoxia-inducible factor-1 (HIF-1) to enhance cell-
matrix adhesion, migration, invasion, and metastasis (Erler et al. 2006). Now, it is widely 
accepted that LOX or LOXL expression correlates with poor prognosis of cancer. LOX 
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expression is a poor prognosis marker of breast (Patani N et al. 2010), head and neck 
squamous cell (Gorogh T et al. 2010), lung (Wilgus ML et al. 2011), prostate, and 
bronchogenic carcinomas while LOXL2 is a poor prognosis marker of lung squamous 
cell carcinomas and larynx squamous cell carcinomas (Peinado H 2008). Upregulation of 
LOXL2 mRNA and/ or protein levels has been detected in the undifferentiated breast 
(Moreno-Bueno G et al. 2011), colon (Kim Y et al. 2009), esophagus (Rost T et al. 2003) 
and larynx (Peinado H et al. 2008) carcinomas. On the other hand, some reports 
demonstrated that LOXL2 expression was inversely related to tumor differentiation grade 
in colon lesions (Fong et al. 2007)  
 
 In relation to LOXL2 and cancer, some studies have suggested that LOXL2 has a 
tumor suppressive role. However, these studies were unable to validate their findings in 
clinical samples. Other studies found a significant decrease in LOXL2 expression in 
several prostate tumor samples (Schmidt H et al. 2007). Recently, in comparison to non-
small cell lung cancer and matched normal tissue, the expression of LOXL2 mRNA and 
protein was shown to be significantly downregulated. Moreover, a significant correlation 
was observed between low LOXL2 expression and lung adenocarcinomas that were 
poorly differentiated and had a high N-stage and advanced pathological TNM stage 
(Zhan, P et al. 2011) (TNM staging is a staging system for classifying cancers in which T 
describes the tumor size, N  describes the involvement of nearby lymph nodes and M 
describes the degree of metastasis) (Barker et al. 2012). 
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In the relation of LOXL2 to metastasis, it has been proposed that LOXL2 
promotes tumor cell survival and chemoresistance, regulates cell adhesion, motility and 
invasion, and remodels the tumor microenvironment. Upregulation of LOXL2 has been 
observed in several human tumors. Studies have shown that increased LOXL2 expression 
is associated with desmoplastic stroma. In addition, LOXL2 can be used as a prognosis 
factor for the increase of risk of recurrence of head and neck SCC. More importantly, 
evidence suggests that high LOXL2 expression is associated with tumor grade, poor 
prognosis and poor overall patient survival (Peng L et al. 2009). Recently, the expression 
of LOXL2 in primary gastric tumors has been associated with tumor invasion, lymph 
node metastasis, and poor overall patient survival. Increased expression of LOXL2 has 
been associated with more aggressive breast cancer in many reports, and has also been 
correlated with metastasis and reduced survival of patients with estrogen receptor (ER)-
negative breast cancer. Together, this evidence may suggest that high LOXL2 expression 
leads to tumor progression and metastasis (Barker et al. 2011) however, more 
investigations need to be done in order to support these claims and understand the exact 
processes involving the role of LOXL2. 
 
Biosynthesis of LOX: 
 The biosynthesis of LOX is a complex, multistep pathway that requires numerous 
post- translational modifications. The processing of prolysyl oxidase to lysyl oxidase first 
begins with lysyl oxidase messenger RNA translation, which produces proLOX, and 
contains 417 amino acids (Grimsby, J et al. 2010).  This proLOX enters into the RER 
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where its signal peptide, a 21 amino acid signal sequence, is cleaved. The N-terminal 
propeptide, comprising of 147 amino acid residues, is then glycosylated within the ER at 
an Asn residue located in the propeptide region (Trackman, P et al. 1992). The C-
terminal sequence, containing the 249 amino acid residue mature protein, is folded while 
acquiring at least three disulfide bonds. The addition of copper, a cofactor of the 
functional catalyst, and the formation of lysine tyrosylquinone cofactor may occur in the 
ER or during protein trafficking through the Golgi body elements. It is then transported 
into vesicles for its secretion into the extracellular space as proLOX, a 50 kDa 
glycoprotein precursor. At the cell surface, the glycosylated N-terminal propeptide of 
proLOX is then proteolytically cleaved between Gly-168 and Asp-169 by procollagen C-
proteinase, releasing a catalytically active mature 32 kDa LOX enzyme (Lucero, et al. 
2006).  
 The LOXL2 mRNA encodes an 87 kDa polypeptide that shares a 48% identity 
with the LOX polypeptide in its amino acid sequence from residue 546 to 751 in its C-
terminal region. This region contains all conserved amino acid sequences needed for the 
proper function of the mature 32 kDa form of the LOX enzyme (Saito, H el at. 1997). 
 
Purification of LOXL2: 
 Purification of enzymatically active recombinant LOX and LOXL proteins is a 
difficult process and producing them in large quantities without losing activity is more 
challenging. Due to the high insolubility and aggregation of inclusion bodies of LOX 
enzyme, purification of the significant yield of recombinant mammalian LOX has been 
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challenging. In the event of producing a significant amount of LOX protein, a refolding 
process is required to be done in order for it to reach an active form. This refolding 
process is time- consuming and leads to significant loss of protein yield and lower 
enzymatic activity and has not been reproducible (Herwald, S et al. 2010).  
 
 The first method that was successful in purifying active forms of LOX and LOXL 
using an E.coli over-expression system, combined with stepwise dialysis to eliminate 
inclusion bodies for refolding (Jung et al 2003). However, this process is impractical, 
time-consuming and leads to loss of protein yield and lower enzymatic activity (Herwald, 
S et al. 2010).  
 
 In 2010, S. E. Herwald aimed to create a method to obtain large yields of purified 
recombinant LOX enzyme without the need of the refolding process using an E. coli 
system and nutrient rich media. A high enzymatic activity of purified LOX was obtained. 
This method was advantageous because it enabled the use of smaller quantities of the 
enzyme for enzymatic assays directly after purification. Direct use of enzyme after 
purification eliminated the loss of enzyme from the refolding process, and also, 
minimized the loss of activity associated with enzyme storage and dialysis (Herwald 
2010). This method was tried later in different labs and happened to be not reproducible.   
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Lentivirus and Adenovirus Vectors: 
 Retroviruses were one of the first viral vectors introduced in gene therapy trials. 
Lentiviruses are part of the retrovirus family which, unlike other viral vectors, can insert 
a specific gene into the host chromosome and support long-term transgene expression. 
Recombinant lentiviruses gene delivery is an efficient method of gene delivery vectors in 
both in vivo and in-vitro experiments. They integrate into the target genome and support 
a stable expression of an affinity tagged cDNA. Their ability to infect a wide range of 
mammalian cell types and transduce nondividing cells is considered as a vital advantage 
(Mak et al. 2012). 
 
 Recombinant adenoviruses (Advs) are one of the most common used approaches 
for efficient in vivo and in vitro gene deliveries. They can deliver genes to both dividing 
and non-dividing cells. Unlike lentiviruses, Advs do not integrate into the host 
chromosomes, and they provide a transient transgene expression that can last for at least 
10 days. In gene therapy, this is considered advantageous because it causes no permanent 
or long term disturbances in genes or cellular processes at the genome within the host 
body. The ease of obtaining high titers, viral particle stability, large packaging capacity of 
foreign DNA, high level of transgene expression and the ability to transduce a wide range 
of tissues and cells including non-dividing cells are crucial advantages for the 
adenovirus- mediated gene delivery. Usually, a green fluorescence protein (GFP), or 
monomeric red fluorescence protein (RFP) is cloned into an adenoviral shuttle vector to 
microscopically insure transduction of host cells (Wang N et al. 2014). 
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Objective 
The aim of this study is to produce large scale enzymatically active recombinant LOXL2 
protein from mammalian cells to evaluate effects on various cell types.  
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Materials and Methods: 
Cell Culture: 
 All cell culture was performed under BL2 sterile conditions in cell culture hood. 
Five different cell lines (293, Parental CHO-K1, previously transduced with lentivirus 
LOXL2 gene CHO-K1, HSC-3, and CAL 27 cells) were cultured. Previously transduced 
and selected CHO-K1 cells and other cell lines were re-cultured. Medium was warmed at 
37°C in a water bath. Each cell line required a different medium. F-12K Kaigh’s 
Modification of Ham’s F-12 Medium (Cat. No. 30-2004; ATCC) supplemented with 1% 
penicillin streptomycin and 10% fetal bovine serum was used for the CHO-K1 (Chinese 
Hamster Ovary cells) cell line. Dulbecco’s Modified Eagle Medium (Cat. No. 11995-065; 
Gibco) supplemented with 1% penicillin streptomycin and 10% fetal bovine serum was 
used for the 293 (Human Embryonic Kidney) cell line. Dulbecco’s Modified Eagle 
Medium (Cat. No. 11995-065; Gibco) supplemented with 1% penicillin streptomycin  
and 10% Bovine Serum, Heat Inactivated (Cat. No. 26170-043; Gibco) was used for 
HSC-3 (squamous cell carcinoma of human oral cancer) and CAL 27 (squamous cell 
carcinoma of human tongue) cell lines. Cells were taken from the -80°C stock and placed 
at room temperature to thaw. Twelve ml of Dulbecco’s phosphate-buffered saline (PBS) 
was pipetted into a sterile labeled 15 ml centrifuge tube. Cells were transferred from their 
vials into their respective labeled centrifuge tube containing PBS and centrifuged for 10 
minutes at 2000 rpm. The supernatant was removed and 6 ml of respective medium was 
added to its correlated centrifugation tube. The medium was pipetted up and down 
several times to ensure that the pellet and cells were properly mixed and distributed and 
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then plated on a 10 cm2 plated with the total of 10 ml of respective medium and 
incubated in humidified atmosphere of 37°C and 5% CO2. Once cells reached 90% visual 
confluence, they were washed with 3 ml of PBS, and trypsinized with 2 ml 0.25% trypsin 
with EDTA (Cat. No. 25200056; Gibco) for five minutes in the incubator, except for 293 
which were trypsinized with 1 ml of 0.25% trypsin with EDTA for 2 minutes. Four ml of 
respective medium was added to the trypsinized plates, pipetted up and down and 
transferred into 15 ml centrifuge tubes and centrifuged for 10 minutes at 2000 rpm to 
remove trypsin from cells. The supernatant was removed, and 6 ml of the respective 
medium was added to the 15 ml tubes, pipetted up and down and plated in 10 cm2 plates. 
The ratio of splitting was 1:3 plates. For previously transduced and selected CHO-K1 
LOXL2 cells, puromycin was added to each plate at 30 µg/ml to insure proper selection 
of cells. After 1-2 days, cells were checked under the microscope, and when they reached 
90% confluence, they were split again at a 1:3 plate ratio. Puromycin, at the same 
concentration, was added only to CHO-K1 cells transduced with LOXL2 gene.  
 
Adenovirus Amplification: 
 The purpose of this procedure was to acquire high titer of the Adenovirus (AdV) 
customized with LOXL2 overexpression vector. Two AdVs were ordered from 
(Genecopoeia) AAV5-CNV-LOXL2 and AAV5-CNV-empty. Both of them have red 
fluorescence protein (RFP) cloned into the adenoviral vector to monitor transduction. All 
cell culture was performed under BL2 sterile conditions in cell culture hood. Two 10 cm2 
plates of the 293 cell line previously cultured were transferred into two 150 cm2 flasks as 
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follows. At 85 to 90% confluency, the two 10 cm2 plates of 293 were washed with 4 ml 
of PBS and trypsinized with 1 ml of 0.25% trypsin with EDTA each for two minutes. 
Four ml of respective medium was added to the trypsinized plates, and transferred into 
two 15 ml centrifuge tubes and centrifuged for 10 minutes at 2000 rpm to remove trypsin 
from cells. The supernatant was removed and 6 ml of the respective medium was added 
to the 15 ml tubes, cells suspended and then transferred into two 150 cm2 flasks. More 
medium was added to reach 20 ml in each flask and cultures were incubated in a 
humidified atmosphere at 37°C and 5% CO2. After cells reached 50% confluence, media 
were changed and 100 µl of Adenovirus AAV5-CNV-LOXL2 and AAV5-CNV-Empty 
were diluted into 1 ml medium into two labeled vials, respectively. One flask was 
transduced with AAV5-CNV-LOXL2 adenovirus and the other flask was transduced with 
AAV5-CNV-Empty Adenovirus and both flasks were labeled. After two days, 20 ml 
medium was added to each flasks and left another two days for the transduction step to 
fully occur. Flasks were checked under the microscope to look for RFP to assure 
transduction. Media were collected into 50 ml labeled tubes for later concentration. Ten 
ml of medium was added to each flask. Mechanical tapping of each flask was used to de-
attach all the cells. Cells were collected into 15 ml labeled centrifuge tubes and 
centrifuged for 10 minutes at 2000 rpm. Media were collected for later concentration and 
5 ml medium was gently added to each tube. Three cycles of 15 minutes freezing, in -
80°C freezer, and thawing, in 37°C water bath, were done to each tube to acquire high 
titer of adenovirus and media were aliquoted into labeled vials and stored in -80°C 
freezer.  
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Determining adenovirus concentration: 
 The purpose of this experiment was to determine the specific concentration of 
adenovirus needed to effectively transduce CHO-K1 cells without killing them. Using 
CHO-K1 cells, 20 thousand cells were plated into a 24-well plate. After 50% visual 
confluence was reached, 1 group of 6 wells was treated as a control group by only 
changing the media. The two other groups were infected with a serial dilution of 
adenovirus; one with empty adenovirus and the other with LOXL2 adenovirus. 500 µl of 
media was added to 2nd, 3rd, 4th and 5th wells. 10 µl of both empty and LOXL2 
adenoviruses were diluted into a 1 ml of medium in a labeled vial. Each 1 ml medium 
was added to the first well of the respective group, mixed well, and 0.5 ml of a medium 
of the first well was added to the next well, and cells suspended. An additional 5 serial 
dilutions were then performed. Wells were labeled according to their order in the serial 
dilution. The plate was cultured for 2 days and was checked under the microscope to 
assure transduction and the appropriate concentration was calculated. 
 
Insuring adenovirus LOXL2 over expression: 
 The purpose of this procedure was to insure that transduction of LOXL2 gene into 
CHO-K1 will lead to LOXL2 over expression. This procedure was done on a small scale 
before producing large amounts of LOXL2 protein. Growth media used was F-12K 
Kaigh’s Modification of Ham’s F-12 Medium (Cat. No. 30-2004; ATCC) supplemented 
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with 1% penicillin streptomycin and 10% fetal bovine serum. Two 150 cm2  flasks were 
used to grow parental CHO-K1 cells. After reaching 5% confluency, the medium was 
changed. One labeled flask was infected with the appropriate concentration of LOXL2 
adenovirus (5 µl per ml of media), and the other flask was infected with empty 
adenovirus, and incubated for 2 days to insure transduction. After reaching 80 to 90% 
visual confluence, both flasks were checked under the microscope to look for RFP to 
insure transduction. Media were removed and each flask was washed with 10 ml of PBS 
3 times and 25 ml of serum-free medium was added, and flasks were incubated for 48 
hours. After 48 hours, media were collected and concentrated to 0.5 ml (50X) for western 
blotting and Coomassie blue staining to check for LOXL2 expression. 
 
Media Collection and Concentration: 
 The purpose of this procedure was to collect large volumes of media in order to 
obtain large yields of enzymatically active protein.  
Lentivirus: 
 Using previously transduced CHO-K1 with lentivirus vector containing LOXL2 
over-expression gene (stable CHO-K1 LOXL2), ten 10 cm2 plates with 85 to 90% cell 
confluency were transferred to ten 150 cm2 flasks. Each flask was growing stable CHO-
K1 LOXL2 in 20 ml of F-12K Kaigh’s Modification of Ham’s F-12 Medium (Cat. No. 
30-2004; ATCC) supplemented with 1% penicillin streptomycin and 10% fetal bovine 
serum. When cells reached 80 to 90% visual confluence, media were changed, and fresh 
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media were added for 1 day. After one day, media were removed and each flask was 
washed with 10 ml of PBS 3 times. 25 ml of serum-free media was added to each flask 
and cells left to be incubated for 48 hours. Serum-free media was collected for later 
purification. Serum-free medium was collected every 48 hours. Between each collection, 
20 ml of complete serum-containing medium was added to each flask and incubated for 1 
day for cells to rejuvenate. When changing from complete medium to serum-free, each 
flask was washed with 10 ml PBS 3 times.  
Adenoviruses: 
 Using an adenovirus transduction system, ten 10 cm2 plates with 85 to 90% cell 
confluency were transferred to ten 150 cm2  flasks. Each flask contained parental CHO-
K1 in 20 ml of F-12K Kaigh’s Modification of Ham’s F-12 Medium ( Cat. No. 30-2004; 
ATCC) supplemented with 1% penicillin streptomycin and 10% fetal bovine serum. After 
reaching 50% visual confluence, media were changed and infected with the appropriate 
concentration of LOXL2 adenovirus (5 µl per ml of media) and incubated for 2 days to 
insure transduction. After reaching 80 to 90% visual confluence, all flasks were checked 
under the microscope looking for RFP to insure transduction. Media were removed and 
each flask was washed with 10 ml of PBS 3 times and 25 ml of serum-free media was 
added and flasks were incubated for 48 hours. After 48 hours, media was collected for 
purification and 20 ml of complete fresh media were added to each flasks and incubated 
for 1 day to allow cells to rejuvenate. After one day, media were removed and each flask 
was washed with 10 ml of PBS. 25 ml of serum-free media were added to each flask and 
collected after 48 hours for purification.  
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Purification of Large Quantities of LOXL2: 
 The purpose of this procedure was to purify large amounts of LOXL2 protein 
from collected culture media. 250 ml of collected media were filtered through a 0.45 µm 
filter. A sample dilution buffer (200 mM sodium phosphate buffer, pH 8.0) was added to 
the filtered media in a 1:1 ratio. Using an automated BioLogic DuoFlow chromatography 
system (BioRad), a nickel affinity column [Bio-Scale Mini Profinity IMAC cartridge 
(BioRad)] was pre-equilibrated with 100 mM of sodium phosphate pH 7.8. Then, the 
sample was run through the nickel affinity column at a flow rate of 4 ml/minute. The 
column was washed with the equilibration buffer until the OD280 reached baseline level. 
The column was eluted with 8 M urea and 0.1 M immidazole, pH 8. The volume of 
elution collected was 25 ml, which was then concentrated to 500 µl using Amicon ultra-
15 PLQK Ultracel Membrane (Cat. No. UFC905024; Millipore) following 
manufacturer’s instructions. Then, the concentrated elution was diluted 2-3 times with 
10% diluted equilibration buffer with no urea and concentrated again to 500 µl. BCA 
Protein Assay Kit from ThermoScientific was used (Cat. No. 23225) to determine the 
protein concentration. The protein sample was then aliquoted, dipped in liquid nitrogen 
for 5 seconds to flash freeze the sample and then stored in - 80ºC freezer. Samples were 
run on an SDS PAGE for Coomassie blue staining SimplyBlue™ SafeStain (Cat. No. 
LC6060; Invitrogen) to asses purity, and to perform Western bolt analysis. 
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BCA Protein Assay: 
 The aim of this procedure was to accurately determine the amount of protein 
present in the concentrated solution after purification of LOXL2. BCA Protein Assay Kit 
from ThermoScientific was used (Cat. No. 23225). Protein standards were prepared by 
adding BSA (2 mg/ml) to a specific amount of working solution (5300 µL reagent A + 
105 µL reagent B) to a total volume of 500 µL. Nine standards were prepared with a BSA 
concentration 2 µg/µl for the first standard, 1.5 µg/µl for the second, 1 µg/µl for the third, 
0.75 µg/µl for the fourth, 0.5 µg/µl for the fifth, 0.25 µg/µl for the sixth, 0.125 µg/µl for 
the seventh. 0.025 µg/µl for the eighth and 0 µg/µl for the last one as a background. 25 µL 
of standards or samples were pipetted into a microplate well then 200 µL of the working 
solution was added to each well. The plate was thoroughly mixed on a shaker for 20 
seconds, covered and incubated at 37˚C for 30 minutes. The plate was cooled to room 
temperature before measuring the absorbance at or near 562 nm on a plate reader. A 
standard curve was generated and data was analyzed on an Excel sheet. 
  
Coomassie blue staining: 
 The purpose of this procedure was to visualize protein bands in medium and 
purified protein on a gel by using electrophoresis. 10% SDS-PAGE gels were loaded with 
equal amounts of proteins (as determined by BCA Protein Assay), sample dilution buffer 
was added to equalize all protein samples used to 40 µL. Four X loading buffer was 
added to each sample at the ratio of 1 to 4 of protein sample and five µL of dye 
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(bromophenol blue) as added to each sample. The total amount of each samples loaded 
was 60 µL. Two protein standards were loaded onto the gels, 10 µL of Pre-Stained SDS-
PAGE BroadRange Standard (Cat. No. 161-0318; BioRad) and 10 µL of Kaleidoscope 
Prestained Standards (Cat. No. 161-0324; BioRad). Using 75 V, gels were run for 120-
150 minutes in the electrophoresis chamber with running buffer (25 mM Tris, 190 mM 
glycine and 0.1% SDS added to 1 L of ultra pure water, pH 8.3) that was made in the lab. 
The gels were removed and adequate amount of SimplyBlue™ SafeStain (Cat. No. 
LC6060; Invitrogen) was used to cover the gel and placed n a horizontal shaker overnight 
at low speed. After 24 hours, the gels were destained with MilliQ water until the bands 
were properly visualized.  
 
Western Blot: 
 The purpose of this procedure was to use gel electrophoresis to separate proteins 
by their molecular weight and identify specific proteins with antibody staining 
procedures on a membrane. 10% SDS-PAGE gels were loaded with equal amounts of 
proteins (as determined by BCA Protein Assay), sample dilution buffer was added to 
equalize all protein samples used to 40 µL. Four X loading buffer was added to each 
sample at the ratio of 1 to 4 of protein sample and five µL of dye was added to each 
sample. The total amount of samples loaded were 60 µL. Two protein standards were 
loaded into the gels, 10 µL of Pre-Stained SDS-PAGE BroadRange Standard (Cat. No. 
161-0318; BioRad) and 10 µL of Kaleidoscope Prestained Standards (Cat. No. 161-0324; 
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BioRad). Using 80 V, gels were run for 120-150 minutes in the electrophoresis chamber 
with running buffer (25 mM Tris, 190 mM glycine and 0.1% SDS added to 1 L of ultra 
pure water, pH 8.3) that made in the lab. Membranes were activated to facilitate protein 
binding by placing them into methanol for 10 seconds, then transfer buffer (3.03 g Tris, 
14.41 g Glycine, 200 ml Methanol, added to 800 ml of ultra pure water, PH 8.3) that 
made by the lab. The gel was removed from the electrophoresis chamber and placed 
between the membrane, blotting paper and sponge for transfer. The placement of the 
membrane in relation to the gel was done to insure the transfer of the protein bands from 
the gel to the membrane. The transfer was done overnight in transfer buffer using 25 V. 
The next day, the membrane was washed with TBS-T (made by the lab out of 20 mM 
Tris pH 7.5, 150 mM NaCl and 0.1% Tween 20) 3 times, first one was for 5 minute the 
other 2 were for 10 minutes. The membrane was then blocked with 5% nonfat dry milk in 
TBS-T (1 g per 20 mL, made by the lab) for 2 hours on a horizontal shaker at room 
temperature. The gel was incubated with primary antibody in the blocking buffer 
overnight at 4°C on a horizontal shaker with gentle agitation. The primary antibodies 
used for the samples were 6x His-Tag (Cat. No. 2365S; Cell Signaling), were diluted at 
1:1000 with TBS-T and used. The next day, the membranes were washed for 10 minutes 
with TBS-T 3 times on a horizontal shaker. The membranes were then incubated with 
anti-Rabbit IgG HRP-linked secondary antibody (Cat. No. 7074S; Cell Signaling) at the 
concentration 1:1000 with TBS-T for 2 hours at room temperature on a horizontal shaker 
with gentle agitation. The membrane was washed with TBS-T 3 times, first one was for 5 
minute the other 2 were for 10 minutes. The membrane was soaked with Immobilon 
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Western Chemiluminescent HRP Substrate (Cat. No. WBKLS0100; Millipore) for 1 min. 
Films were developed in the darkroom and analyzed. 
 
Amplex Red Assay: 
 The purpose of this experiment was to measure enzyme activity in purified 
protein samples. Two buffers were prepared and labeled as Buffer 1 and Buffer 2. Buffer 
1 consisted of 50 mM borate, 1.2 M urea brought to a pH of 8.2. Buffer 2 consisted of 50 
mM of borate, 6 M urea brought to a pH of 8.2. A horseradish peroxidase was prepared 
as 170 units/ml, the cadaverine as 200 mM, BAPN as 10 mM, hydrogen peroxide as 8.7 
uM, and Amplex® Red Reagent (Cat. No. A12222; Life Technologies) as 1 mM. All 
with MilliQ water except for Amplex® Red Reagent which was with DMSO. Triplicates 
were prepared for all samples and standards. All glass tubes were labeled before starting 
the experiment. Each protein sample was divided into two groups; the first group 
contained BAPN (LOX inhibitor), second group was not to contain BAPN. Triplicates for 
each group were used. For those samples containing BAPN, the buffers (multiplied by 
the number of samples and triplicates) were added to make a master mix in the following 
order: 379.5 µL of buffer 1, 3.0 µL of HRP, 12.5 µL of buffer 2, 25 µL of BAPN, 25 µL 
of cadaverine, and 5 µL of Amplex red. Once the master mix was made, 450 µL from this 
master mix was pipetted into each glass tube, along with 50 µL of sample. For those 
triplicates not containing BAPN, the buffers (multiplied by the number of samples and 
triplicates) were added in the following order: 404.5 µL of buffer 1, 3 µL of HRP, 12.5 
µL of buffer 2, 25 µL of cadaverine, and 5 µL of Amplex red.  From this master mix, 450 
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µL was pipetted into the glass tubes along with 50 µL of its respective sample. Once 
mixed, the samples were incubated for 30 minutes at 37°C. In LOXL2 samples obtained 
from lentivirus batches number 1, 2, 3 and 4, and LOXL2 samples obtained from 
adenovirus batch number 1, 3 µg of LOXL2 was loaded in this experiment. In LOXL2 
samples obtained from lentivirus batches number 5 and 6, and LOXL2 samples obtained 
from adenovirus batch number 2, 3 and 4, 1 µg of LOXL2 was loaded in this experiment. 
Triplicates of the standards were prepared at varying concentrations of hydrogen 
peroxide so that the final total volume of each standard was equal to 500 µL. The 
standards were prepared as a master mix when the samples had 10 minutes left to finish 
the incubation period for both reactions to coincide. Standards’ master mix were prepared 
in the following order of addition of buffers: buffer 1, HRP, cadaverine, and Amplex 
Red. The varying amounts of buffer 1 was accounted for by adding the difference to each 
glass tube. Hydrogen peroxide was then added once the master mix was pipetted into 
each glass tube to reach a final concentration of hydrogen peroxide of 0 nM, 88 nM, 176 
nM, 264 nM, 352 nM, 440 nM and 528 nM, respectively. The standards were then 
incubated for 5 minutes at 37°C. After incubation, the tubes were kept on ice to stop the 
reaction. Each tube was mixed well and 200 µL from each was transferred to a black, 
non-binding 96 well plate. Using the MikroWin program, the settings were as follows: 
Initial delay 5 minutes, shake 10s, 2 repeats, 2500 lamp energy, and normal excitation by 
plate. End-point fluorescence was measured and data was analyzed in an Excel 
spreadsheet. 
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Cyquant Proliferation Assay: 
 The aim of this procedure is to determine the effect of LOXL2 recombinant 
protein on cell proliferation by determining cell density in culture. All cell culture was 
performed under BL2 sterile conditions in cell culture hood. Two cell lines were use in 
this experiment HSC-3 (metastatic) and CAL 27 (non-metastatic). Dulbecco’s Modified 
Eagle Medium (Cat. No. 11995-065; Gibco) supplemented with 1% penicillin 
streptomycin and 10% Heat Inactivated Bovine Serum (Cat. No. 26170-043; Gibco) was 
used as growth medium. Each cell line was plated in 2 different cell densities (20,000 and 
50,000 cells per well) in a 24-well plates. Each seeded density of cells were designed as 
follows: 6 wells were seeded and labeled as day zero in a separate plate, 6 wells were 
seeded and labeled as a control group and 6 wells were seeded for each LOXL2 
conditions (0.2 µg/ml, 0.5 µg/ml, 1 µg/ml, 2 µg/ml and 5 µg/ml). Once cells reached 
more than 50% confluency, cells were washed with PBS 3 times and starved in 
Dulbecco’s Modified Eagle Medium (Cat. No. 11995-065; Gibco) supplemented with 1% 
penicillin streptomycin and 0.5 % heat-inactivated bovine serum, for one day. Wells that 
were labeled as day zero were washed once with PBS and stored in -80 ºC freezer in 
preparation for Cyquant assay experiment.  
 Medium was changed to control labeled wells with same medium of 0.5% heat 
inactivated bovine serum. Five 50 ml centrifuge tubes were labeled for each condition 
and the appropriate volume of media and LOXL2 protein were added to each tube and 
mixed well. Each well was washed with 0.5 ml of PBS 3 times and respective medium 
was added to each well and incubated for 24 hours. Plates were checked under the 
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microscope and washed once with PBS and stored in -80 ºC freezer in preparation for 
Cyquant assay experiment. The same process was done to a duplicate group of both cell 
lines with difference of changing the medium from 10% to 0.5 % Heat Inactivated 
Bovine Serum. 
 The Cyquant cell proliferation assay kit (Catalog No. C-7026) was used to assess 
LOXL2 effects on cell proliferation. On the day of each experiment, cells were thawed at 
room temperature for 30 minutes. A 20 ml working solution was prepared by mixing 1 ml 
of cell-lysis buffer with 19 ml of MilliQ water and 100 µl of Cyquant GR stock solution 
and mixed well in a 50 ml centrifugal tube that is wrapped with aluminum foil. 990 µl 
was taken from the working solution into a vial to prepare the standards. Ten µl of 
bacteriophage λ DNA standard was added to the vial of 990 µl and was labeled DNA 
solution. Nine standards were prepared by adding specific volume of DNA solution to a 
specific volume of working solution to reach a total volume of 200 µl. Nine vials were 
labeled from 1 to 9 and were prepared with different DNA solution volumes. First 
standard was prepared with 0 µl, second was 2 µl, 3rd was 10 µl, 4th was 20 µl, 5th was 
40 µl, 6th was 80 µl, 7th was 120 µl, 8th was 160 µl and 9th was 200 µl. Final DNA 
concentration of all standards from 1 to 9 in ng/ml were ( 0, 10, 50, 100, 200, 400, 600, 
800 and 1000) respectively. Vials were mixed well and pipetted into a black 96-well 
micro plate. 200 µl of working solution were added into each well of the samples and left 
for five minutes. 150 µl of solution that was added to the samples were pipetted into a 
black 96-well plates and fluorescence was measured for ~480 nm excitation and ~520 nm 
emission maxima on a plate reader. Standard curve was generated and data was analyzed 
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on an Excel sheet. 
Results: 
LOXL2 Enzyme Expression in Cell Medium: 
 The CHO-K1 LOXL2 media samples obtained after purification with His-Tag 
mini-columns from two different methods of transduction, lentivirus transduction and 
adenovirus transduction, were run in an SDS-PAGE with a Coomassie blue staining and a 
western blot. The Coomassie blue staining of the gel showed several bands including two 
bands at 70 kDa and 112 kDa as shown in Figure 1. To confirm the expression of LOXL2 
in the samples a western blot was done. An equal volume of LOXL2 media protein (40 
µL) was loaded into the gels for Western blot. The blot showed expression of two bands 
of LOXL2 at 70 kDa and 112 kDa in both samples with a stronger expression with 
adenovirus as shown in Figure 2.  
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Figure 1: Coomassie Blue staining of a 10% gel shows two bands of LOXL2, 
one at 112 kDa and the second one at 70 kDa in LOXL2 transduced CHO-K1 
cell medium. 
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Figure 2: Western Blot with primary antibody anti-(his)6 and secondary 
antibody anti-rabbit IgG coupled to HRP shows expression of two bands of 
LOXL2: one at 112 kDa and the second one at 70 kDa in LOXL2 transduced 
CHO-K1 cell medium with a stronger expression of adenovirus verses 
lentivirus. Top picture exposure time was 5 seconds and bottom picture 
exposure time was 20 seconds. 
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LOXL2 Purification in Large Quantities: 
 A Bio-Scale Mini Profanity IMAC cartridge (BioRad) was used to purify LOXL2 
enzyme generated from Advs. The purified LOXL2 enzyme was concentrated and was 
subjected to SDS-PAGE and a Coomassie blue staining and Western blot. The gel of the 
Coomassie blue staining from Adenovirus transduced CHO-K1 cells showed stronger 
two bands around 112 kDa and 70 kDa compared to Lentivirus transduced cells as 
showed in Figure 3. The Western blot was done to confirm the expression of the purified 
LOXL2 from both methods, it showed two stronger bands of LOXL2 expression from 
Adenovirus transduced cells at 112 kDa and 70 kDa compared Lentivirus transducer cells 
as showed in Figure 4. 
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Figure 3: Coomassie Blue staining of a 10% gel shows stronger two bands of 
LOXL2 from 2 batches of Adenovirus transduced cells compared to Lentivirus 
transduced cells at 112 kDa and 70 kDa. 
 
		 31	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Western Blot with primary antibody anti-His and a secondary anti-
rabbit IgG coupled to HRP shows stronger two bands of LOXL2 from 2 
batches of Adenovirus transduced cells compared to Lentivirus transduced 
cells at 112 kDa and 70 kDa. 
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BCA Protein Quantification Assay: 
 In order to calculate the concentration and amount of purified LOXL2 proteins, 
the concentrated protein sample was quantified using a BCA protein quantification assay. 
In this assay, a standard curve of absorbance verses protein concentration was produced 
as seen in Figure 5. Based on the linear equation obtained from the standard curve, the 
concentration of protein (µg/µl) was calculated for the samples and the total amount of 
protein obtained from each batch was also calculated as shown in Table 1. 
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Figure 5: Standard curve of absorbance versus protein concentration of the CHO-K1 
control and LOXL2 transduced cells. 
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	 Concentration of protein 
as calculated from BCA 
Assay 
Total yield of protein 
as calculated from 
BCA Assay 
Batch #1 of lentivirus transduced 
Cells 408 µg/ml 0.204 mg 
Batch #2 of lentivirus transduced 
Cells 484 µg/ml 0.242 mg 
Batch #3 of lentivirus transduced 
Cells 320 µg/ml 0.176 mg 
Batch #4 of lentivirus transduced 
Cells 285 µg/ml 0.150 mg 
Batch #5 of lentivirus transduced 
Cells 470 µg/ml 0.211 mg 
Batch #6 of lentivirus transduced 
Cells 208 µg/ml 0.124 mg 
Batch #1 of Adenovirus transduced 
Cells 285 µg/ml 0.242 mg 
Batch #2 of Adenovirus transduced 
Cells 670 µg/ml 0.470 mg 
Batch #3 of Adenovirus transduced 
Cells 733 µg/ml 0.440 mg 
Batch #4 of Adenovirus transduced 
Cells 609 µg/ml 0.460 mg 
 
Table 1: Protein concentrations and total yield of each batch based on the equation 
derived from the standard curve of fluorescence. 
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Comparison of LOXL2 Protein Yields from Adenovirus and Lentivirus 
Transduced Cells: 
 Purified LOXL2 Protein yields from Adenovirus and lentivirus transduced cells 
were compared. Using a T-test, a statistically significant difference (P<0.05) were found 
between adenovirus transduced cells compared to lentivirus transduced cells in favor of 
adenovirus transduced cells as showed in Figure 6. 
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Figure 6: The averages of protein yields from adenovirus and lentivirus transduced 
cells was compared. Data are from Table 1. A statistically significant difference 
(P<0.05) in protein yields was found in favor of adenovirus transduced cells. 
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LOXL2 Enzyme Activity in Amplex Red Assay: 
 In order to calculate LOXL2 enzymatic activity, an Amplex red assay was done 
according to the protocol descried in the Material and Methods section. End-point 
fluorescence was measured and analyzed in an Excel spreadsheet. The triplicates of the 
standards were averaged and the standard deviations and relative standard deviations 
were calculated. The averaged fluorescence value (fluorescence unit) of the reagent blank 
(0 µg/µL) was subtracted from the average fluorescence value of each standard. The 
corrected values were then used to generate a standard curve of fluorescence versus nM 
of H2O2, as can be seen in Figure 7. The fluorescence reading for the triplicates of the 
samples (one treated with BAPN and the other untreated) were averaged and the standard 
deviations were calculated. The average fluorescence reading of the sample with BAPN 
was then subtracted from the averaged fluorescence reading without BAPN, which 
resulted in the y-axis value. With the y-axis value known, the nM of H2O2 was then 
calculated based on the equation of the graph. The y axis value was normalized by 
dividing the corrected average fluorescence reading by the protein concentration (µg/µL) 
of its respective medium, measured in the BCA quantification assay.  
 The averaged fluorescence read-outs and activity values for the purified LOXL2 
from lentivirus transduced cells for all 6 batches are described in Table 2 and for all 4 
Adv batches are described in Table 3. The concentration of H2O2 generated by 50 µL of 
200x concentrated samples (activity/µg) in all lentivirus transduced cells were calculated 
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to be 1112.93 nM, 801.17 nM, 878.81 nM, 745.26 nM, 263.14 nM and 1456.8 nM in 30 
min, respectively. From these concentrations, the specific LOXL2 activity generated in 
30 minutes at 37°C was calculated in all 6 lentivirus batches to be 0.556 nmol/µg, 0.401 
nmol/µg, 0.439 nmol/µg, 0.372 nmol/µg, 0.131 nmol/µg and 0.728 nmol/µg, respectively. 
The concentration of H2O2 in 50 µL of 200x concentrated samples (activity/µg) in all 
adenovirus transduced cells were calculated to be 293.89 nM, 1188.16 nM, 1055.32 nM 
and 1013.29 nM respectively. From these concentrations, the specific LOXL2 activity 
generated in 30 minutes at 37°C was calculated in all 4 adenovirus batches to be 0.147 
nmol/µg, 0.594 nmol/µg, 0.572 nmol/µg and 0.506 nmol/µg, respectively. The average 
total activity for lentivirus and adenovirus transduced cells were 76.9 nmol and 195 nmol, 
respectively. 
 In order to test for differences in the specific activity of LOXL2 enzyme obtained 
from lentivirus and adenovirus transduction, the calculated enzymatic activities were 
averaged in both groups as illustrated in Figure 8 and a T-test was done. No significant 
difference was found (P>0.05) in LOXL2 enzymatic activity between both methods.  
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Figure 7: H2O2 standard curve of average fluorescence versus nM of H2O2.  
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Table 2: Averaged fluorescence read-outs and enzymatic activity for LOXL2 
transduced cells using a lentivirus vector without BAPN. Data are after subtraction 
of the BAPN control. 
 
 
 
Background 
adjusted 
fluorescence value 
divided by 1000 
Total yield of 
Protein as 
calculated from 
BCA 
Concentration 
of  H2O2 
produced in 
Amplex Red 
LOXL2 
Activity Assays 
(activity/μg) 
Specific 
activity of 
LOXL2 
enzyme in 
30 
minutes  
Total 
activity of 
LOXL2  
Sample of batch #1 
without BAPN 
837.5 fluorescence 
units 0.204 mg 1112.93 nM 
0.556 
nmole/µg 
113.42 
nmol 
Sample of batch #2 
without BAPN 
604.7 fluorescence 
units 0.242 mg 801.17 nM 
0.401 
nmole/µg 
97.04 
nmol 
Sample of batch #3 
without BAPN 
662.7 fluorescence 
units 0.176 mg 878.81 nM 
0.439 
nmole/µg 
77.26 
nmol 
Sample of batch #4 
without BAPN 
563.1 fluorescence 
units 0.150 mg 745.26 nM 
0.372 
nmole/µg 55.8 nmol 
Sample of batch #5 
without BAPN 
122.5 fluorescence 
units 0.211 mg 263.14 nM 
0.131 
nmole/µg 
27.64 
nmol 
Sample of batch #6 
without BAPN 
675.3 fluorescence 
units 0.124 mg 1456.8 nM 
0.728 
nmole/µg 
90.27 
nmol 
Average 577.63 fluorescence units 0.1845 mg 876.36 nM 
0.438 
nmole/µg 76.9 nmol 
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Background 
adjusted 
fluorescence value 
divided by 1000 
Total yield of 
Protein as 
calculated from 
BCA 
Concentration 
of  H2O2 
produced in 
LOXL2 
Amplex Red 
Activity 
Assays 
(activity/μg) 
Specific 
activity of 
LOXL2 
enzyme in 
30 
minutes 
Total 
activity of 
LOXL2 
Sample of batch #1 
without BAPN 
226.2  fluorescence 
units 0.242 mg 293.89 nM 
0.147 
nmol/µg 
35.56 
nmol 
Sample of batch #2 
without BAPN 
550.9  fluorescence 
units 0.470 mg 1188.16 nM 
0.594 
nmol/µg 
279.22 
nmol 
Sample of batch #3 
without BAPN 
489.4 fluorescence 
units 0.440 mg 1055.32 nM 
0.527 
nmol/µg 
232.17 
nmol 
Sample of batch #4 
without BAPN 
469.9 fluorescence 
units 0.460 mg 1013.29 nM 
0.506 
nmol/µg 
233.05 
nmol 
Average 434.1 fluorescence units 0.403 mg 887.67 nM 
0.444 
nmol/µg 195 nmol 
 
Table 3: Averaged fluorescence read-outs and enzymatic activity for LOXL2 
transduced cells using an adenovirus vector without BAPN. Data are after 
subtraction of the BAPN control. 
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Figure 8: Averaged specific LOXL2 enzyme activity obtained from lentivirus 
transduction and from adenovirus transduction methods. No statistical significant 
difference was found (p>0.05). 
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Effect of LOXL2 Enzyme on Metastatic and Non Metastatic Cancer Cell 
Lines in Cyquant Proliferation Assay: 
 In order to determine the effect of LOXL2 enzyme on cell proliferation, a 
Cyquant proliferation assay was done according to the description explained in the 
Materials and Methods section. End point fluorescence was measured and analyzed in an 
Excel spreadsheet. In order to insure the effect of the working solution a standard curve 
of the fluorescence readings was generated out of the number of standard verses the 
concentration of DNA in ng/ml as seen in Figure 9. The fluorescence reading of the 
triplicates of each treatment conditions of both HSC-3 and CAL 27 cells lines were 
calculated and averaged in an excel spread sheet.  
 For CAL 27 cell line data did not reveal stimulation of cell growth by LOXL2 
treatment. For the HSC-3 cell lines in different medium conditions, an observation was 
seen under the microscope after treatment with LOXL2 at 0.1 µg/ml and 0.5 µg/ml.  Cells 
formed a second partially detached layer in all three wells of each treatment condition 
which might have totally detached later at the step of PBS washing. The average DNA 
fluorescence reading for the 0.5% serum medium found in Figure 10 was 7556.2 unit of 
fluorescence for the control group (0 µg/ml of LOXL2), 9452.7 unit of fluorescence for 
0.1 µg/ml of LOXL2, 9703 unit of fluorescence for 0.5 unit of fluorescence of LOXL2, 
8399.7 unit of fluorescence for 2 µg/ml of LOXL2 and down to 3610.3 unit of 
fluorescence for 5 µg/ml of LOXL2. The average DNA fluorescence reading for the 10% 
serum medium found in Figure 11 was 8397 unit of fluorescence for 0 µg/ml of LOXL2, 
9605.3 unit of fluorescence for 0.1 µg/ml of LOXL2, 10462.3 unit of fluorescence for 0.5 
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µg/ml of LOXL2, 9832.3 unit of fluorescence for 2 µg/ml of LOXL2 and 8420 unit of 
fluorescence for 5 µg/ml of LOXL2. No statistical significance was found (P >0.05), but 
consistent increase in cell proliferation was noticed in 0.1 µg/ml and 0.5 µg/ml groups 
followed by a consistent decrease in cell proliferation in 2 µg/ml and 5 µg/ml groups.  
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Figure 9: Standard curve of a number of standard versus final DNA concentration. 
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Figure 10: The average DNA fluorescence of HSC-3 in 0.5 % medium with different 
treatment conditions of LOXL2. 
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Figure 11: The average DNA fluorescence of HSC-3 in 10 % medium with different 
treatment conditions of LOXL2. 
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Discussion: 
 After the discovery of the novel family of LOX proteins and their involvement in 
a wide range of functions and important roles in disease activities, the production of large 
quantities of enzymatically active forms of LOX or LOXL proteins in vitro has been very 
difficult (Jung et al 2003). 
 
 The aggregation and high insolubility of LOX are some of the reasons that make 
its purification in large amounts very challenging. Kagan, utilizing CHO cells, and Di 
Donato, utilizing E. coli, were successful in expressing small amounts of LOX. In one 
study that were able to purify LOX through stepwise dialysis, a refolding of the protein 
was required in order to reach active forms (Jung et al 2003). This refolding process is 
time-consuming and leads to significant loss of protein yield and lower enzymatic 
activity. In another method involving the use of E. coli system and nutrient rich media, a 
high enzymatic activity of purified LOX was obtained. Both methods were tried later by 
different labs and happened to be not reproducible. Furthermore, the large molecular 
weight of LOXL2 might increase the difficulty in purifying this protein.  
 
 The previous methods used in these studies for the production of recombinant 
LOX included the use of E. coli. The techniques used in these methods will need to 
transform E.coli microorganisms with a bacterial expression plasmid vector and allow 
these bacteria cells to grow in LB medium containing ampicillin under certain conditions. 
Isopropyl-β-D-thiogalactopyranoside (IPTG) is then added and the bacteria are permitted 
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to incubate for a set amount of time. Cells then are collected and centrifuged. Preceding 
cell extraction, cells are resuspended in lysis buffer and cell lysis occurs by sonication. 
Lysates are then centrifuged to remove the debris and afterward the supernatants are 
further centrifuged to isolate inclusion bodies which by high- speed centrifugation, which 
are then solubilized, incubated and diluted. The arrangement is at last dialyzed 
extensively against PBS; this will help LOX to precipitate then be collected by 
centrifugation (Ouzzine, Boyd, and Hulmes 1996).   
 
 The problem with using a prokaryotic host, in this case E. coli, to produce 
recombinant proteins is that E. coli lacks the glycosylation pathway. N-linked 
glycosylation is the most common type of glycosidic bond and is important for the 
folding of proteins such as LOX. Normally in eukaryotes, this glycosylation occurs in the 
lumen of the endoplasmic reticulum, but very rarely in bacteria. The resulting 
recombinant expressed LOX derived from E. coli from the above methods is non-
glycosylated due to the absence of the glycosylation pathway. The optimal activity of a 
secretory enzyme such as LOX depends on the acquisition of a native conformation 
through its folding pathway within the lumen of the endoplasmic reticulum and the 
associated post-translational modifications, such as glycosylation, that occur throughout 
the secretory pathway. The lack of glycosylation in the propeptide results in a defective 
folded structure leading to a mature LOX with reduced activity (Grimsby, J et al. 2010). 
The presence of glycosylations assist post-translational protein folding and once this is 
achieved, the removal of the carbohydrate structure does not affect the protein folding 
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and function. The mature LOX enzyme does not contain N-glycosylation after it is 
separated from its pro-peptide and remains catalytically functional. Since optimal activity 
of mature LOX is derived from a glycosylated pro-peptide, and the glycosylation 
pathway is present in eukaryotic cells, it is to our advantage to employ a mammalian 
expression system rather than the previously used eukaryotic systems. For LOXL2, the 
fact that this protein is understudied and the source of its activity is not fully understood 
yet, its logical to try to purify an optimum recombinant form of LOXL2 without the 
elimination of the glycosylation pathway occurring in prokaryotes. 
 
 For the current study, the aim is to create a method to purify large amounts of 
enzymatically active forms of recombinant LOXL2 from mammalian cells in a 
predictable and reproducible way. This method will maintain the enzyme yield and its 
activity. For this reason, CHO-K1 cells were chosen to purify recombinant LOXL2. It 
was found that the enzyme activity of the purified recombinant LOXL2 using CHO-K1 
cells was 7.1-fold of the control cells. In this method, two viral vector systems were used 
and reproduced in order to optimize the protocol and the procedure outcome. Using a 
lentivirus vector allows permanent integration to the cell’s chromosomes facilitating a 
continuous overexpression of the target protein. The average yield of this method was 
184.5 µg/ml (SD± 43.1). Although this method produced a relatively high yield of 
purified active enzyme compared to previous methods described in the literature, we 
found that the amount of protein obtained by these methods are variable and not 
predictable when the protein is needed to be used for different experiments. In order to 
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increase the yield obtained without losing enzymatic activity, an adenovirus vector 
system was used to transiently transfect CHO-K1 cells (Wang N et al. 2014). In this 
method, the yield of LOXL2 protein was 403 µg/ml (SD± 108). This yield demonstrates 
an increase by 2.18 folds without losing enzymatic activity when compare to lentivirus 
vector system. This increase was not only statistically significant (P= 0.0018) but also 
had practical significance. With increasing the LOXL2 protein yield without statistically 
significance difference in enzymatic specific activity (P=0.89), The total activity was 
statistically significant (P= 0.08, P< 0.05). The average total activity for lentivirus and 
adenovirus transduced cells were 1847.4 and 4793.3 nmol respectively.   The significant 
increase in total activity could be attributed to the significant increased yield of LOXL2 
obtained by the adenovirus transduced method. The practicality of have more protein is 
advantageous in allowing to use each batch in the mandatory experiments that needs to be 
done like measuring protein yield and activity using BCA quantification assay or Amplex 
red assay to gain information of protein concentration and enzymatic activity respectively 
without losing a significant amount of protein purified in each batch. Furthermore, it 
allows to standardize and optimize the results obtained when testing the effect of LOXL2 
through multiple experiments by using a single batch of purified LOXL2 protein, 
eliminating the variability that may be faced when using different batches of purified 
LOXL2 protein for these experiments. The Western blot confirmed the expression of 2 
bands of LOXL2 at 112 and 70 kDa in the medium of the transduced cells in both 
lentivirus and adenovirus transduced cells. The molecular weight of LOXL2 was 
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described in the literature to be around 100 kDa (Vadasz et al. 2005 and Hollosi et al. 
2009). 
 
 In a Cyquant assay done on the effect of different treatment conditions of LOXL2 
on metastatic cancer cells (HSC-3 cells), no statistical significance was found (P >0.05) 
but consistent increase in cell proliferation was noticed in 0.1 µg/ml and 0.5 µg/ml groups 
followed by consistent decrease in cell proliferation in 2 µg/ml and 5 µg/ml groups. This 
decrease could be attributed to the possibility that these doses could have a toxic effect on 
the cell line leading to cell death, though this was not experimentally determined. Also, 
the fact that the increase in cell proliferation under both treatment conditions was not 
statistically significant might be attributed to the fact that HSC-3 cells can express 
LOXL2 in amounts sufficient for accomplishing near to its maximum proliferative effect. 
Additional experiments are needed to distinguish between these possibilities. 
 
 In this study, although purified LOXL2 protein showed a strong expression of 2 
bands at 112 kDa and 70 kDa, many faint bands at other molecular weights were present 
when the SDS-PAGE gel stained with coomassie blue was visually assessed. This 
indicates that an extra purification step may be required to be done in order to achieve a 
purer form of the LOXL2 Protein. This is critical when applying mechanistic type of 
experiments. Studying a protein with a high percentage of purity would minimize the 
chance of reactivity with the undesired protein background thus providing a more 
accurate results of the enzymatic effect of the target protein. When comparing the 
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average specific activity of LOXL2 with the activity of LOX reported in previous papers 
(Palamakubura A. et al 2001), our data shows that the average value of LOXL2 activity 
was 0.444 nmol/µg of LOXL2 in 30 minutes. While LOX activity reported in the 
mentioned article was 0.135 nmol. This demonstrates a 3.2 folds’ increase of specific 
activity of LOXL2 when compared to LOX. This suggest that the specific activity of 
LOXL2 is higher than LOX. When comparing LOXL2 activity with the same protein 
previously purified in our lab, it shows a 13 folds’ increase of LOXL2 activity obtained 
in this report compared to the one made in our lab before which was 0.034 nmol. This 
study showed the expression of catalytically active recombinant LOXL2 in the medium 
of mammalian cells. This expression gives way to studies that can lead to the purification 
of optimally active high yields of enzyme. Mechanistic, kinetic and substrate specificity 
studies will be greatly facilitated by the ability to harvest LOXL2 in high quantities and 
in repeatable and predictable method. Expression and purification will also bring us 
closer to elucidating a crystal structure of LOXL2, which will gain insight into the 
structure-function relationships of this catalyst. From a clinical aspect, the purification of 
these enzymes will allow us to investigate the medicinal properties of LOXL2, such as its 
role in cancer activity.  
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